Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial
| Autor: | Adam Bisaga, Cale Basaraba, Martina Pavlicova, Daniel J. Brooks, Amy L. Mahony, Frances R. Levin, C. Jean Choi, John J. Mariani, Nasir H. Naqvi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Swine Narcotic Antagonists Toxicology Placebo Naltrexone Article Lorcaserin law.invention Injections 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Outpatients medicine Animals Humans Pharmacology (medical) 030212 general & internal medicine Pharmacology business.industry Opioid use disorder Benzazepines Middle Aged medicine.disease Opioid-Related Disorders Buprenorphine Substance Withdrawal Syndrome Clinical trial Psychiatry and Mental health Delayed-Action Preparations Female business human activities 030217 neurology & neurosurgery Methadone medicine.drug |
| Zdroj: | Drug Alcohol Depend |
| ISSN: | 1879-0046 |
| Popis: | Background Opioid Use Disorder (OUD) is a significant public health problem associated with severe morbidity and mortality. While effective pharmacotherapies are available, limitations exist with each. Induction onto extended-release naltrexone (XR-NTX) is more difficult than initiation of buprenorphine or methadone, even in inpatient settings, as it is recommended that patients remain abstinent for at least 7 days prior to initiating XR-NTX. The purpose of this trial was to determine if lorcaserin, a 5HT2c agonist, improves outpatient XR-NTX induction rates. Methods An 8-week trial beginning with a brief detoxification period and induction onto XR-NTX. Sixty participants with OUD were enrolled in the trial, with 49 participants at the initiation of detoxification randomized to lorcaserin or placebo for 39 days. Additionally, ancillary medications were provided. The primary outcome was the proportion of participants inducted onto the first XR-NTX injection. Secondary outcomes were withdrawal severity (measured by COWS and SOWS) prior to the first injection and the proportion of participants receiving the second XR-NTX injection. Results The proportion of participants inducted onto the first (lorcaserin: 36 %; placebo: 44 %; p = .67) and the second XR-NTX injection (lorcaserin: 27 %; placebo: 31 %; p = .77) was not significantly different between treatment arms. Prior to the first injection, withdrawal scores did not significantly differ between treatment arms over time (treatment*time interaction COWS: p = .11; SOWS: p = .39). Conclusions Lorcaserin failed to improve outpatient XR-NTX induction rates. Although this study is small, the findings do not support the use of lorcaserin in promoting induction onto XR-NTX or in mitigating withdrawal symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect